AB248

Phase 1Small molecule

Amgen

AB248 is one of 95 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerNot yet recruiting

Small Cell Lung CancerRecruiting

Triple-Negative Breast CancerPhase 1

Not yet recruiting

Small Cell Lung CancerPhase 1

Recruiting

Competition

Competitive Landscape

154 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

33 2

Imfinzi

AstraZeneca

Phase 3

30 3

Tecentriq

Roche

Phase 3

27 4

Camptosar

Pfizer

Phase 3

26 5

Keytruda

Merck & Co.

Phase 3

20 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

96 7

Avastin

Roche

Phase 3

16 8

Vepesid

Opdivo

Tarlatamab-Dznl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Recruiting

Small Cell Lung Cancer

NCT07037758

Q2 2035

Phase 1Not yet recruiting

Triple-Negative Breast Cancer

NCT07300475

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Recruiting· Amgen logo

Amgen·Phase 1·NCT07037758·380 enrolled

Triple-Negative Breast Cancer1 trial

Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy +/- AB248 (CD8-selective IL-2 Mutein Fusion Protein) in Patients With a New Diagnosis of Triple Negative Breast Cancer Undergoing Neoadjuvant Chemoimmunotherapy

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07300475·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AB248. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB248 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB248. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Amgen

AB248

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q2 2035

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News